None
EVAX 20-FMar 5 '26
“In 2025, MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) licensed Evaxion's vaccine candidate EVX-B3 for a cash payment of $7.5 million, and Evaxion is eligible for future development, regulatory and sales milestone payments as well as royalties on net sales”
PSNL 10-KFeb 26 '26
“our future business with the U.S. Department of Veterans Affairs' Million Veteran Program ("VA MVP"), ModernaTX, Inc. ("Moderna"), Merck & Co., Inc. ("Merck"), and other collaboration partners and customers;”